Cardinal Health (CAH) Q4 2026 earnings review
Core Strength and One-Time Boosts Drive EPS, but Cracks Show in Smaller Segments
Cardinal Health capped off Fiscal 2026 with an optically massive quarter, reporting a 40% surge in Q4 Non-GAAP EPS to $2.91. However, $0.31 of this came from a one-time IEEPA tariff refund. Excluding this windfall, EPS still grew a highly respectable 25%. The core Pharmaceutical segment remains the engine, delivering 21% profit growth on sustained specialty demand. Unprecedented free cash flow generation ($5.0 billion adjusted) fueled a new $5.0 billion buyback authorization. Yet, beneath the strong headline numbers, the 'Other' high-growth segment is abruptly decelerating, and the GMPD medical unit's underlying operations are actually shrinking. Management's FY27 guidance targets 13-15% underlying EPS growth, signaling confidence that capital deployment and Pharma momentum can offset weakness elsewhere.
🐂 Bull Case
The core Pharmaceutical and Specialty Solutions segment delivered 21% profit growth in Q4, vastly outpacing its 6% revenue growth. The segment expanded its margin to 1.10% from 0.97% a year ago.
Adjusted free cash flow doubled year-over-year to $5.0 billion in FY26. Management is aggressively returning this to shareholders, replacing a completed $1.4B buyback with a massive new $5.0 billion authorization.
🐻 Bear Case
The Global Medical Products and Distribution (GMPD) segment reported a 114% profit increase, but this is entirely artificial. Stripping out a $100M tariff refund, underlying Q4 profit collapsed 29% YoY on shrinking revenues.
The 'Other' segment (at-Home, Nuclear, OptiFreight), touted as the high-growth future, saw revenue growth abruptly decelerate to 7% in Q4 from 31%+ in prior quarters, as the boost from recent acquisitions annualized.
⚖️ Verdict: ⚪
Neutral-to-Bullish. The core Pharma business is executing flawlessly and capital returns provide a massive floor for the stock. However, the alarming deceleration in the 'Other' segment and the underlying deterioration in GMPD prevent a perfectly clean bill of health.
Key Themes
Pharmaceutical Segment Margin Leverage
Pharma continues to act as Cardinal's anchor. Despite top-line revenue decelerating from earlier quarters to a stable 6% YoY ($58.8B), segment profit accelerated to 21% YoY ($645M). The spread between volume growth and profit growth indicates excellent operational leverage, strong generic program contributions, and a favorable mix shift toward Specialty therapies.
The GMPD Headline Illusion
Management's press release highlights GMPD segment profit rising to $150M in Q4 (from $70M). This is highly misleading. A $100M IEEPA tariff refund masks severe underlying weakness. Excluding the refund, Q4 GMPD profit was just $50M—a 29% YoY contraction. Furthermore, segment revenue actually reversed, falling 2% YoY due to lower distribution volumes. The business is still struggling with core profitability once the one-time macro relief is stripped away.
Severe Deceleration in 'Other' Growth Segments
The 'Other' segment (Nuclear, OptiFreight, at-Home) has been a primary growth driver throughout FY26, routinely posting 30%+ revenue and profit growth fueled by the ADS acquisition and secular tailwinds. In Q4, this trend reversed hard. Revenue growth collapsed to just 7% YoY, and profit growth decelerated to 14%. While management is executing tuck-in M&A (Strive Medical, AdaptHealth Diabetes) to re-stoke the engine, the organic momentum appears to be cooling rapidly.
Capital Returns: A Massive Floor for the Stock
Cardinal's cash generation is becoming its biggest strategic asset. Following the generation of $5.0B in adjusted FCF in FY26, the Board approved a gargantuan $5.0 billion increase to the share repurchase authorization (bringing the total available to $6.4 billion). Alongside the simplification of its credit facilities to a new $4.0B revolver, CAH possesses immense financial flexibility to aggressively shrink the float while absorbing tuck-in M&A.
Network Modernization and Automation
The company is actively modernizing its distribution footprint to drive future margin expansion. Cardinal announced a new distribution center in Indianapolis (opening in 2027) that will specifically feature advanced robotics and automation. This aligns with prior tech rollouts like the Vantus HQ ordering platform to improve operational flexibility and lower SG&A intensity over the long term.
Macro Tailwind: Tariff Recoveries Finally Materialize
After multiple quarters of warning about tariff headwinds pressuring the GMPD segment, Cardinal successfully recognized a one-time net operating profit impact of $100M from IEEPA tariff refunds in Q4 (net of expected repayments to customers). While positive, this is a non-recurring macro relief event rather than an operational breakthrough.
SG&A Creep Needs Monitoring
GAAP Distribution, selling, general and administrative (SG&A) expenses rose 10% YoY in Q4 to $1.62B. Even when excluding recent acquisitions, organic SG&A grew 8% YoY ($1.42B). With revenue growth slowing to 6%, this creates a negative leverage divergence that management must keep in check to protect operating margins.
Other KPIs
An absolute standout metric. Adjusted FCF essentially doubled from $2.49B in FY25. This was driven heavily by exceptional working capital management, notably a $3.46B increase in accounts payable that dwarfed inventory builds, fueling the massive expansion in shareholder returns.
A reminder of past M&A friction. Total FY26 impairments hit $177M, primarily reflecting the pre-tax goodwill impairment charge taken earlier in the year related to the Navista & ION reporting unit due to a strategic pivot. While non-cash, it highlights integration and valuation risks as Cardinal executes new tuck-ins like Strive Medical.
Guidance
Accelerating structurally. The midpoint of $12.50 implies 14% growth when measured against the 'adjusted' FY26 base of $10.95 (which strips out the $0.31 one-time tariff refund). This is above the company's long-term EPS guidance framework.
Decelerating. A clear step down from the exceptional 23% profit growth achieved in FY26. Management expects top-line revenue to slow to 3-5%, indicating that while margins remain healthy, the massive wave of new customer onboarding and M&A from FY26 is fully entering the base.
Accelerating. Generating $210M at the midpoint represents a ~33% growth rate over the adjusted FY26 baseline of $158M (excluding the tariff refund). Management anticipates a return to top-line growth (2-4%), suggesting confidence that internal cost improvements will outpace remaining tariff drag.
Stable. While this is significantly lower than the 37% growth posted for full-year FY26, it aligns with the Q4 exit rate (14%) and indicates stabilization following the annualized impact of prior acquisitions. The new tuck-ins (Strive, AdaptHealth) will be required to maintain this trajectory.
Decelerating from FY26's record $5.0B, reflecting normalization of the outsized working capital/accounts payable benefits recognized this year. It remains robust enough to fully fund the ~$1.0B in planned FY27 share repurchases.
Key Questions
GMPD Bridge to $200M+
Excluding the IEEPA refund, Q4 GMPD profit was just $50M on negative revenue growth. What are the specific structural cost take-outs or pricing actions driving confidence in the $200-$220M profit guidance for FY27 given underlying weakness?
M&A Strategy in 'Other' Segment
Organic revenue growth in the 'Other' segment slowed to 7% in Q4. How much of the 11-13% FY27 revenue growth guidance relies on the newly announced tuck-in acquisitions (Strive Medical, AdaptHealth) versus organic acceleration?
Pacing the $5B Buyback
With the massive $5.0B expansion to the repurchase authorization and $1B targeted for FY27, how does management view the remaining capital capacity for larger-scale M&A in the specialty space versus accelerating stock buybacks?